IP Library Granted Patent US 7,698,180
Granted Patent B2
US 7,698,180 · App. 11/618,065 · Granted Apr 13, 2010

System for tracking data relating to radiopharmaceuticals and/or containers therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,698,180
App. No.
11/618,065
Granted
Apr 13, 2010
Kind
B2
Abstract

The present invention relates to management of information relating to medical fluids, containers therefor, and medical fluid administration devices for administering such medical fluids to patients. Data tags (e.g., RFID tags) are generally associated with containers of the invention and may be electromagnetically read from and/or written to using an electromagnetic device, for example, that may be associated with a medical fluid administration device of the invention.

Claims (35)

1. A system for tracking data relating to a radiopharmaceutical in a container, the container having a RFID tag operable to have data written thereto and read therefrom, the system comprising:

a filling station operable to fill the container with the radiopharmaceutical and comprising a filling station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical;

a calibration station comprising a calibration station electromagnetic device configured to write data to the RFID tag relating to a radioactivity level of the radiopharmaceutical in the container; and

a treatment room comprising a treatment room electromagnetic device configured to write data to the RFID tag relating to administration of the radiopharmaceutical to a patient.

2. The system of claim 1 , further comprising:

a hospital information system in electrical communication with the filling station, calibration station, and/or treatment room electromagnetic device(s).

3. The system of claim 2 , further comprising:

a disposal station comprising a disposal station electromagnetic device configured to write data to the RFID tag relating to disposal of the container.

4. The system of claim 3 , further comprising:

a packaging station operable to place the container in a radiopharmaceutical pig.

5. The system of claim 4 , wherein the packaging station comprises a packaging station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical, the container, and/or the radiopharmaceutical pig.

6. The system of claim 2 , further comprising:

a storage area comprising a storage area electromagnetic device configured to write data to the RFID tag relating to placing the container into and/or removing the container from the storage area.

7. The system of claim 2 , further comprising:

a packaging station operable to place the container in a radiopharmaceutical pig.

8. The system of claim 7 , wherein the packaging station comprises a packaging station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical, the container, and/or the radiopharmaceutical pig.

9. The system of claim 2 , wherein the hospital information system comprises a IS electromagnetic device configured to read data from and/or write data to the RFID tag.

10. The system of claim 9 , further comprising:

a disposal station comprising a disposal station electromagnetic device configured to write data to the RFID tag relating to disposal of the container.

11. The system of claim 10 , further comprising:

a packaging station operable to place the container in a radiopharmaceutical pig.

12. The system of claim 11 , wherein the packaging station comprises a packaging station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical, the container, and/or the radiopharmaceutical pig.

13. The system of claim 9 , further comprising:

a packaging station operable to place the container in a radiopharmaceutical pig.

14. The system of claim 13 , wherein the packaging station comprises a packaging station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical, the container, and/or the radiopharmaceutical pig.

15. The system of claim 1 , further comprising:

a disposal station comprising a disposal station electromagnetic device configured to write data to the RFID tag relating to disposal of the container.

16. The system of claim 15 , further comprising:

a packaging station configured to place the container in a radiopharmaceutical pig.

17. The system of claim 16 , wherein the packaging station comprises a packaging station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical, the container, and/or the radiopharmaceutical pig.

18. The system of claim 1 , further comprising:

a packaging station operable to place the container in a radiopharmaceutical pig.

19. The system of claim 18 , wherein the packaging station comprises a packaging station electromagnetic device configured to write data to the RFID tag relating to the radiopharmaceutical, the container, and/or the radiopharmaceutical pig.

20. The system of claim 1 , further comprising:

a storage area comprising a storage area electromagnetic device configured to write data to the RFID tag relating to placing the container into and/or removing the container from the storage area.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 041131/0213 →